{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '20', 'References', '(1) Medicinal Products Act (Arzneimittelgesetz AMG) in the version published on 12', 'December 2005 (Federal Law Gazette [BGBI.]) Part I p. 3394, last amended by Article', '1 of the Ordinance of 10 October 2013 (BGBI. I S. 3813). 2013 Oct.', '(2) ICH E6 (R2) - Guideline for Good Clinical Practice. 2016.', '(3) Declaration of Helsinki, 64th WMA General Assembly, (2013).', '(4) Handa S. Newer trends in the management of psoriasis at difficult to treat locations:', 'scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol 2010', 'Nov;76(6):634-44.', '(5) Kragballe K. Management of difficult to treat locations of psoriasis. Scalp, face,', 'flexures, palm/soles and nails. Curr Probl Dermatol 2009;38:160-71 doi:', '0.1159/000232309. Epub@2009 Jul 28.:160-71.', '(6) Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas.', 'Clin Dermatol 2008 Sep;26(5):448-59.', '(7) Griffiths C, Camp R, Barker J. Psoriasis. In: Burns T, Breathnack S, Cox N, et al.,', \"editors. Rook's Textbook of Dermatology.Massachusetts Oxford, Victoria: Blackwell\", 'Science; 2004. p. 52-3.', '(8) Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and', 'clinical review with introduction of a new quality-of-life assessment tool. J Am Acad', 'Dermatol 2009 Jun;60(6):1024-31.', '(9)', 'Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar', 'pustulosis: a double-blind comparative trial. Br J Dermatol 1988 Dec;119(6):755-9.', '(10) Layton AM, Sheehan-Dare R, Cunliffe WJ. A double-blind, placebo-controlled trial of', 'topical PUVA in persistent palmoplantar pustulosis. Br J Dermatol 1991', 'Jun;124(6):581-4.', '(11) Adisen E, Tekin O, Gulekon A, Gurer MA. A retrospective analysis of treatment', 'responses of palmoplantar psoriasis in 114 patients. J Eur Acad Dermatol Venereol', '2009 Jul;23(7):814-9.', '(12) Marsland AM, Griffiths CE. Treatments for chronic palmoplantar pustular psoriasis.', 'Skin Therapy Lett 2001 Nov;6(12):3-5.', \"(13) V'Ickova-Laskoska MT, Caca-Biljanovska NG, Laskoski DS, Kamberova SJ.\", 'Palmoplantar pustulosis treated with itraconazole: a single, active-arm pilot study.', 'Dermatol Ther 2009 Jan;22(1):85-9.', '(14) Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral', 'liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-', 'blind, placebo-controlled study. Br J Dermatol 2001 Oct;145(4):546-53.', '(15) Reich K, Graff O, Mehta N. Oral alitretinoin treatment in patients with palmoplantar', 'pustulosis inadequately responding to standard topical treatment: a randomized phase', 'Il study. Br J Dermatol 2016 Jun;174(6):1277-81.', 'Page 64 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '(16) Gerdes S, Franke J, Domm S, Mrowietz U. Ustekinumab in the treatment of', 'palmoplantar pustulosis. Br J Dermatol 2010 Nov; 163(5) 1116-8.', '(17)', 'Bissonnette R, Nigen S, Langley RG, Lynde CW, Tan J, Fuentes-Duculan J, et al.', 'Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-', 'plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled', 'trial. J Eur Acad Dermatol Venereol 2014 Oct;28(10):1298-305.', '(18) Morales-Munera C, Vilarrasa E, Puig L. Efficacy of ustekinumab in refractory', 'palmoplantar pustular psoriasis. Br J Dermatol 2013 Apr;168(4):820-4.', '(19)', 'Buder V, Herberger K, Jacobi A, Augustin M, Radtke MA. Ustekinumab in der Therapie', 'der Pustulosis palmoplantaris - Eine Fallserie mit neun Patienten. J Dtsch Dermatol', 'Ges 2016 Nov;14(11):1109-15.', '(20) Bissonnette R, Poulin Y, Bolduc C, Maari C, Provost N, Syrotuik J, et al. Etanercept in', 'the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008 Oct;7(10):940-6.', '(21)', 'Guenther LC. Alefacept is safe and efficacious in the treatment of palmar plantar', 'pustulosis. J Cutan Med Surg 2007 Nov;11(6):202-5.', '(22) Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a', 'selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014', 'Sep;26(9):2016-29.', '(23) Schafer PH, Chen P, Fang L, Wang A, Chopra R. The pharmacodynamic impact of', 'apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory', 'biomarkers in patients with psoriatic arthritis: substudy results from a phase III,', 'randomized, placebo-controlled trial (PALACE 1). J Immunol Res 2015;2015:906349.', 'doi: 10.1155/2015/906349. Epub@2015 Apr@20.:906349', '(24) Boehncke WH, Schon MP. Psoriasis. Lancet 2015 Sep 5;386(9997):983-94.', '(25) Talbot J, Bianchini FJ, Nascimento DC, Oliveira RD, Souto FO, Pinto LG, et al. CCR2', 'Expression in Neutrophils Plays a Critical Role in Their Migration Into the Joints in', 'Rheumatoid Arthritis. Arthritis Rheumatol 2015 Jul;67(7):1751-9.', '(26) Hagforsen E, Hedstrand H, Nyberg F, Michaelsson G. Novel findings of Langerhans', 'cells and interleukin-17 expression in relation to the acrosyringium and pustule in', 'palmoplantar pustulosis. Br J Dermatol 2010 Sep;163(3):572-9.', '(27) Murakami M, Hagforsen E, Morhenn V, shida-Yamamoto A, lizuka H. Patients with', 'palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and', 'serum. Exp Dermatol 2011 Oct;20(10):845-7', '(28) Bissonnette R, Pariser DM, Wasel NR, Goncalves J, Day RM, Chen R, et al.', 'Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar', 'psoriasis: Results of a pooled analysis from phase Il PSOR-005 and phase III Efficacy', 'and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical', 'trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016', 'Jul;75(1):99-105.', '(29) EMA. Summary of the risk management plan (RMP) for Otezla (apremilast). 2014 Dec.', 'Page 65 of 75']\n\n###\n\n", "completion": "END"}